This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Eprodisate
DrugBank Accession Number
DB06405
Background

Eprodisate slows the decline of renal function in AA amyloidosis.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 204.21
Monoisotopic: 203.976230326
Chemical Formula
C3H8O6S2
Synonyms
  • 1,3-propanedisulfonic acid
  • Eprodisate
  • Propane-1,3-disulfonate
  • Propane-1,3-disulfonic acid
  • Propane-1,3-disulphonate
External IDs
  • NC-503

Pharmacology

Indication

Investigated for use/treatment in amyloidosis.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Decline in renal function associated with Amyloid A (AA) amyloidosis can be slowed by eprodisate (Kiacta), a drug that inhibits the deposit of the complex protein in tissues. AA amyloidosis is a serious, frequently fatal disorder involving deposits of amyloid fibrils in various organs and tissues. It is a complication of many chronic inflammatory disorders, but little is known about its etiology or natural history. Eprodisate delays the progression of AA amyloidosis-associated renal disease.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Kiacta

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
6QFP76V7S7
CAS number
21668-77-9
InChI Key
MGNVWUDMMXZUDI-UHFFFAOYSA-N
InChI
InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)
IUPAC Name
propane-1,3-disulfonic acid
SMILES
OS(=O)(=O)CCCS(O)(=O)=O

References

General References
Not Available
ChemSpider
379112
ChEMBL
CHEMBL2111092
ZINC
ZINC000005225211
Wikipedia
1,3-Propanedisulfonic_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionAmyloidosis1
2CompletedTreatmentSyndrome, Metabolic / Type 2 Diabetes Mellitus1
2, 3CompletedTreatmentFamilial Mediterranean Syndrome / Gastrointestinal Diseases / Kidney Diseases / Nephrotic Syndrome / Rheumatoid Arthritis / Secondary (AA) Amyloidosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.2 mg/mLALOGPS
logP-2.6ALOGPS
logP-1.7ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)-2ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area108.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity36.21 m3·mol-1ChemAxon
Polarizability16.64 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at March 19, 2008 16:29 / Updated at February 21, 2021 18:52